Clinical Trial Update: Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a multi-agent regimen of rituximab, bendamustine hydrochloride, and bortezomib, followed by rituximab and lenalidomide, in older pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bendamustine Hydrochloride (bendamustine)
• Bortezomib (bortezomib)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Lymphoma, Mantle Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-08